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Case Report
Abstract
Pompe disease is a lysosomal storage disorder that results from an inborn error of metabolism which involves abnormal glycogen storage. 
Infantile-onset Pompe disease is the most severe phenotype that manifests with the findings of hypotonia, generalized muscle weakness, 
feeding difficulties, a failure to thrive, hearing loss, hypertrophic cardiomyopathy with systolic dysfunction, and respiratory distress. There is 
no effective treatment for Pompe disease and clinical control includes primary support health care. However, recent studies have reported 
that enzyme replacement therapy (ERT) can effectively decrease the symptoms or severity of the disease. The present study is a case report 
of a 24-day patient with infantile-onset Pompe disease who presented coughing and respiratory distress. The infant experienced fatigue 
during breastfeeding from the birth and developed dry and nonproductive coughs and perioral cyanosis from two weeks after the birth. 
The echocardiogram demonstrated left and right ventricular enlargement, mitral and tricuspid regurgitation, and pulmonary hypertension. 
After definitive diagnosis, the patient was administered with 20 mg/kg of alglucosidase 50 mg vial once every two weeks. He experienced 
significant improvement in body weight and echocardiogram and symptoms such as fatigue during breastfeeding and perioral cyanosis 
disappeared completely while he was under Myozyme treatment. In general, the observations confirmed the efficacy of Myozyme in 
a patient with infantile Pompe disease. Therefore, early diagnosis and quick treatment of Pompe disease with Myozyme can lead to 
acceptable outcomes, improve conditions, and finally, increase the chance of survival in these patients.
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Introduction 
Pompe disease, also called type II glycogen storage 
disease, is a rare autosomal recessive inherited disease 
which is caused by the storage of glycogen in lysosome 
due to acid α-glucosidase (GAA) deficiency (1). GAA 
deficiency causes the accumulation of glycogen in the cell 
and impairs the cell structure and function, leading to a 
multisystem disease and early death (2). The incidence 
rate of Pompe disease is very low and it occurs in less than 
one per one hundred thousand live births (3). As a clinical 
entity, the disease has been known for over 75 years. While 
an optimist might be excited about the advances made 
during this time, a pessimist would note that we have 
yet to find a cure (4). Pompe disease includes two major 
phenotypes, including infantile-onset and late-onset 
Pompe disease that differ in their characteristics based 
on the age at the onset, organ involvement, severity, and 
the rate of progression (5). Infantile-onset Pompe disease 
may manifest in utero but more often is diagnosed at 3-4 
months of age with the findings of hypotonia, generalized 
muscle weakness, feeding difficulties, a failure to thrive, 
hearing loss, hypertrophic cardiomyopathy with systolic 
dysfunction, and respiratory distress. In addition, feeding 
difficulties may result from facial hypotonia, macroglossia, 
tongue weakness, and poor oral motor skills. The patients 
are likely to die within the first year of life (6,7). There 
is no effective treatment for Pompe disease and the 
clinical control only includes the primary support health 
care. However, recent studies have reported that enzyme 
replacement therapy (ERT) can effectively reduce the 
symptoms or severity of the disease (8,9). The reported 
case is the first case of Pompe disease in Chaharmahal and 
Bakhtiari who underwent enzyme therapy with Myozyme 
and responded to the treatment. The patient’s conditions 
improved and he survived for more than one year. 
Case Presentation
The patient was a 24-day infant who was referred from 
one of the counties of the province. The infant had been 
hospitalized due to coughing and respiratory distress 
and diagnosed with pneumonia and thus was treated 
with antibiotic therapy. During the examinations, 
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echocardiography was conducted by an adult cardiologist 
and the patient was referred to our center due to left 
and right ventricular enlargement, mitral and tricuspid 
regurgitation, and pulmonary hypertension. 
Due to the above-mentioned symptoms, the infant 
experienced fatigue during breastfeeding from the birth 
and developed dry and nonproductive coughs and perioral 
cyanosis since 2 weeks after his birth. In our center, 
electrocardiography (ECG) and echocardiography were 
ordered because cardiomegaly was observed in the chest 
X-ray (Figure 1). 
The ECG showed increased voltage in most cardiac 
leads and decreased PR interval (Figure 2).
Further, the echocardiography demonstrated the 
enlargement and hypertrophy of both ventricles, atrial 
enlargement, mitral and tricuspid regurgitation, and 
pulmonary hypertension with SPAP 50 mmHg (Figure 3).
As a result, treatment with lasix, sildenafil, and captopril 
was started to control pulmonary hypertension. Regarding 
the symptoms and examinations results, the suspected 
diagnosis was Pompe disease. The laboratory Pompe 
disease test conducted at the Pompe Disease Genetic 
Center in Tehran was sent to Germany and after 3 weeks, 
the positive Pompe disease test was received and the 
diagnosis was confirmed.
After the parents were informed, the infant underwent 
periodical treatment with Myozyme. In the first three 
administrations of the drug, the infant was hospitalized in 
our center and received the necessary health care. Because 
the family of the baby lived in one of the villages near 
Lordegan and it was difficult for them to commute to 
Shahrekord (the capital of the Province) the treatment 
was continued in Lordegan cunty. For the baby, 20 mg/kg 
bodyweight of alglucosidase 50mg vial was administered 
by intravenous infusion within 6 hours once every 2 
weeks. The examinations demonstrated that the infant’s 
conditions began to improve such that his weight reached 
8.5 kg at 18 months of age while his birth weight was 3 kg. 
The serial echocardiogram indicated that the left ventricular 
wall thickness of 12 mm reached 7-8 mm. Moreover, the 
pulmonary pressure of 50 mm Hg decreased to 30 mm 
Hg and the administration of drugs was discontinued and 
the symptoms such as fatigue during breastfeeding and 
perioral cyanosis disappeared completely. 
Discussion 
It is difficult to diagnose Pompe disease because of the 
rarity and relatively nonspecific nature of the phenotypic 
characteristics. Many diseases can be included in the 
differential diagnosis of Pompe disease such as idiopathic 
hypertrophic cardiomyopathy, myocarditis, spinal 
muscular atrophy type 1, and congenital muscular atrophy 
(10). A high level of clinical suspicion is necessary for a 
timely and accurate diagnosis (11). Chest X-ray and 
electrocardiogram are the screening tests for diagnosing 
Pompe disease in infants. Echocardiography is the next 
diagnostic measure as well. Chest X-ray reflects the severity 
of cardiomegaly. ECG of these patients indicates short 
PR intervals and very tall QRS complexes. In a sample 
of 19 infants with Pompe disease, the PR intervals of 14 
infants were short (12). In infants with Pompe disease, it 
is common to observe hypertrophic cardiomyopathy with 
or without the obstruction of left ventricular outflow tract 
in the early stages of the disease. In the final stages of the 
disease, dilated cardiomyopathy and cardiac dysfunction 
may be detected as well. Additionally, for patients with 
cardiomyopathy, an electromyogram can be useful 
for diagnosing myopathy before the emergence of the 
symptoms. The blood tests such as the measurement of 
blood creatine kinase are considered sensitive but non-
specific tests for Pompe disease (13). Taken together, the 
clinical diagnosis of the disease is confirmed by measuring 
Figure 1. Chest X-ray.
Figure 2. Pompe disease electrocardiography.
Figure 3. Initial echocardiography.
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α-glucosidase in the tissues and the decline in its activity. 
Gene analysis is the gold standard for the diagnosis of 
Pompe disease. Conventional methods such as skin and 
muscle biopsies and dried blood spot test have certain 
limitations for the diagnosis of this disease. In recent 
years, prenatal diagnosis and newborn screening have 
played an important role in its early diagnosis (1). Pompe 
disease is regarded as a multisystem disease and a team 
including the cardiologist, pulmonologist, neurologist, 
physiotherapist, and speech therapist should cooperate 
with each other for its treatment (14). A number of 
clinical trials on Pompe disease in infants demonstrated 
that ERT can significantly increase the survival, decrease 
cardiomyopathy, and improve the functions of the heart 
and skeletal muscles in these patients (15-18). Without 
ERT, patients with infantile-onset Pompe disease develop 
cardiomegaly and hypertrophic cardiomyopathy that 
progress to left ventricular outflow obstruction, as well as 
systolic and diastolic dysfunction (6,7). The most optimal 
response of the skeletal muscles is reported in patients 
who are treated immediately and before the development 
of severe muscular injuries. However, some patients fail 
to satisfactorily respond to treatment despite starting 
quick treatment. It seems that certain factors such as the 
disease stage at the onset of the treatment and immune 
responses to the neo-compound enzyme contribute to 
the response to enzyme therapy (14). New targeted gene 
therapy and modified ERT will be put into practice in the 
future (1). Meanwhile, new trials in Pompe disease based 
on gene therapy are currently ongoing (19). However, 
the treatment of severe cardiac disease remains quite 
challenging (20-22).
Considering the role of genetics in Pompe disease, it 
should be noted that the parents of the case presented 
in this report were second-degree relatives, and after 
diagnosis confirmation, they were advised to receive 
genetic counseling before the next pregnancy. 
The other family members of the patient were also 
suggested to attend genetic counseling sessions but they 
refused due to financial problems.
It is also recommended that genetic counseling be 
conducted for first-degree relatives before marriage, but it 
is not recommended for other consanguineous marriages 
due to the rarity of the disease and the lack of evidence on 
the incidence of the disease in the children of the other 
consanguineous couples.
Conclusion 
Considering the favorable results of the treatment of the 
reported infantile Pompe disease with Myozyme, early 
diagnosis and quick treatment with Myozyme can bring 
about acceptable outcomes, improve the conditions, and 
increase survival in these patients. 
Because the primary presentations of Pompe disease 
in infants are nonspecific and physicians have little 
information about this disease, the symptoms are 
frequently attributed to other diseases, which causes 
delayed diagnosis, and consequently, the treatment is not 
started early. Therefore, although Pompe disease is a rare 
one, the physicians should always consider this disease 
since the consequent cardiac and respiratory problems 
may lead to the death of the affected infants if they are not 
early diagnosed and treated with Myozyme.
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